Any toxicity (> CTCAE version  grade ) from previous anti-cancer therapy that has not resolved to a grade ; persistence of clinically relevant therapy related toxicity from previous chemo and/or radiotherapy; patients with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy, alopecia)
Any unresolved toxicity (> CTCAE version [v] grade ) from previous anti-cancer therapy; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripheral neuropathy)
Any unresolved toxicity Common Terminology Criteria for Adverse Events (CTCAE) grade >=  from previous anti-cancer therapy; exceptions include hearing loss, peripheral neuropathy, and alopecia
Any unresolved toxicity (Common Terminology Criteria for Adverse Events [CTCAE] grade >= ) from previous anti-cancer therapy. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy).
Any unresolved toxicity (? Common Terminology Criteria for Adverse Events [CTCAE] grade ) from previous anti-cancer therapy. NOTE: Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)
Any unresolved toxicity (> Common Terminology Criteria for Adverse Events [CTCAE] grade ) from previous anti-cancer therapy, excluding alopecia. Subjects with irreversible toxicity greater than grade  that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy).
Any unresolved toxicity (> Common Terminology Criteria for Adverse Events [CTCAE] grade ) from previous anti-cancer therapy; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)
Is still experiencing toxicity related to prior treatment and assessed as Common Terminology Criteria for Adverse Events (CTCAE) grade > . Exceptions are alopecia and/or anorexia. The eligibility of patients who are still experiencing irreversible toxicity that is not reasonably expected to be exacerbated by the study drugs in this study (eg, hearing loss) must be reviewed and approved by both the principal investigator and medical monitor
Any unresolved toxicity (Common Terminology Criteria for Adverse Events [CTCAE] grade >= ) from previous anti-cancer therapy; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)
Any unresolved toxicity (Common Terminology Criteria for Adverse Events [CTCAE] grade  or above) from previous anti-cancer therapy; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)
Any unresolved Common Terminology Criteria for Adverse Events (CTCAE) grade > toxicity from previous anti-cancer therapy; patients with irreversible toxicity that is not reasonably expected to be exacerbated by study therapy (eg, hearing loss) may be enrolled after discussion with the principal investigators
Any unresolved toxicity (> Common Terminology Criteria for Adverse Events [CTCAE] grade ) from previous anti-cancer therapy; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)
Any unresolved toxicity (> Common Terminology Criteria for Adverse Events [CTCAE] grade ) from previous anti-cancer therapy; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)
Any unresolved toxicity (CTCAE grade < ) from previous anti-cancer therapy; (subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)
Any unresolved toxicity Common Terminology Criteria for Adverse Events (CTCAE) grade  or more from previous anti-cancer therapy, except alopecia, hearing loss, peripheral neuropathy or non-clinically significant laboratory abnormalities
Any unresolved toxicity (> Common Terminology Criteria for Adverse Events [CTCAE] grade ) from previous anti-cancer therapy with the exception of alopecia; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripheral neuropathy)
Any unresolved toxicity (> CTCAE grade ) from previous anti-cancer therapy; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)
Any unresolved toxicity (> CTCAE grade ) from previous anti-cancer therapy; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., alopecia, hearing loss, peripheral neuropathy)
Any unresolved clinically significant treatment related toxicity of >= grade  intensity, as assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), from previous anti-cancer therapy; patients with irreversible toxicity (eg, hearing loss, peripherally neuropathy) or reversible toxicity (eg, alopecia) that is not reasonably expected to be exacerbated by the investigational product and is not expected to interfere with study participation may be included
Any unresolved toxicity (> CTCAE grade ) from previous anti-cancer therapy; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)
Any unresolved toxicity from previous anti-cancer therapy must have resolved to at least =< grade  (or baseline) at time of enrollment\r\n* Patients with irreversible toxicity that is not reasonably expected to be exacerbated by treatment with durvalumab and tremelimumab may be included after consultation with the principal investigator or co-principal investigator (e.g. alopecia, hearing loss, peripheral neuropathy)